We’re pleased that the European Summit supports open dialogue and the sharing of best practices around utilizing advanced automation and data management to dramatically enhance productivity.
Sunnyvale, CA (PRWEB) October 02, 2014
Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced highlights of its European Summit, held September 23 - 24, 2014 at GlaxoSmithKline (GSK) in Ware, UK. The meeting featured customer case studies and discussions of best practices in high throughput research and data management.
At this year’s Summit, R&D leaders gathered together to discuss the challenges and opportunities for high throughput research in drug development. The Summit consisted of formal case-study presentations by a diverse set of customers including GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, and Novo Nordisk, who highlighted their experience with Freeslate products to achieve dramatic innovation and rapid return on investment. Hands-on training sessions were given by Freeslate staff who focused on accelerating productivity. Networking between sessions and at evening events offered attendees opportunities for one-on-one discussions and to exchange new strategies and ideas.
“The customer success stories and dialogue demonstrate the significant advancements that European pharmaceutical development organizations have been making,” said John S. Senaldi, President and CEO of Freeslate. “We’re pleased that the European Summit supports open dialogue and the sharing of best practices around utilizing advanced automation and data management to dramatically enhance productivity.”
Some of the key success stories that were highlighted at the Summit included using data generated from automation systems to build predictive models for drug stability, as well as creative approaches to linking data from high throughput systems back to knowledge management systems. Other concepts included approaches to utilizing automation equipment to investigate new chemical research areas, methods accelerating the development of biologics formulations, and the value of the user-friendly, walk-up interface on the Freeslate CM Protégé Powder Dispense System.
Freeslate offers unique, high throughput systems to address drug development applications. Based on the Freeslate Core Module 3 and CM Protégé automation platforms, Freeslate offers automation solutions for biologics formulation, small molecule preformulation, and process chemistry, all linked to a powerful data management suite for getting the most out of the data generated.
Freeslate is a privately held company providing laboratory automation products that dramatically improve the productivity and innovation of drug development organizations. For more than a decade, Freeslate has been working with customers to automate complex chemical research processes. Our resulting product line includes solutions for protein and vaccine drug formulation development, small molecule solubility, and polymorph screening and process chemistry. We start with a scientific understanding of our customer’s bottlenecks and utilize our robust and proprietary automation platforms and integrated Lab Execution and Analysis (LEA) software suite to deliver solutions that make a difference. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.